Atrial fibrillation therapy in patients with a CRT defibrillator with wireless telemetry

PACE - Pacing and Clinical Electrophysiology

Volumn 32, Issue 1, 2009, Pages 13-23

  Crossley, George H ^a,k   Aonuma, Kazutaka ^b   Haffajee, Charles ^c   Shoda, Morio ^d   Meijer, Albert ^e   Bauer, Alexander ^f   Boriani, Giuseppe ^g   Svendsen, Jesper ^h   Thomas, Shelley ⁱ   Wiggenhorn, Christopher ⁱ   Unterberg Buchwald, Christina ^j  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

^c ST ELIZABETH'S MEDICAL CENTER   (United States)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e CATHARINA HOSPITAL   (Netherlands)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h Rigshospitalet   (Denmark)

ⁱ MEDTRONIC INC   (United States)

^j UNIVERSITY OF GÖTTINGEN   (Germany)

^k Pulmonary Disease Program   (United States)

more..

Author keywords

Atrial fibrillation; Atrial shock therapy; Cardiac resynchronization therapy; Cardioversion; Implantable cardioverter defibrillator; Wireless telemetry

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; CONVULSIVE THERAPY; DEFIBRILLATOR; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; RISK ASSESSMENT; TELEMETRY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; INCIDENCE; INTERNATIONALITY; MALE; MIDDLE AGED; SURVIVAL RATE; TELEMETRY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58149267839     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2009.02171.x     Document Type: Article

References (42)

1. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 1991 84 : 40 48.
2. Centers for Disease Control and Prevention (CDC). Atrial fibrillation as a contributing cause of death and Medicare hospitalization-United States, 1999. MMWR - Morb Mortal Wkly Rep 2003 52 : 128 131.
3. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics-2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007 115 : e69 e171.
4. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, Sutton GC. Incidence and aetiology of heart failure; A population-based study [see comment]. Eur Heart J 1999 20 : 421 428.
5. Tuinenburg AE, Van GI, Van Den Berg MP, Brugemann J, De Kam PJ, Crijns HJ. Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation. Heart 1999 82 : 486 493.
6. Darbar D, Warman EN, Hammill SC, Friedman PA, Worldwide JAI, Darbar D, Warman EN, et al. Recurrence of atrial tachyarrhythmias in implantable cardioverter-defibrillator recipients. Pacing Clin Electrophysiol 2005 28 : 1047 1051.
7. Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JG, Freemantle N, Erdmann E. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 2006 114 : 18 25.
8. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998 82 : 2N 9N.
9. Khand AU, Cleland JG, Deedwania PC. Prevention of and medical therapy for atrial arrhythmias in heart failure [Review;128 refs]. Heart Fail Rev 2002 7 : 267 283.
10. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, et al. Cardiac resynchronization in chronic heart failure [see comments]. N Engl J Med 2002 346 : 1845 1853.
11. Abraham WT, Young JB, Leon AR, Adler S, Bank AJ, Hall SA, Lieberman R, et al., on behalf of Multicenter ICD II Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter- defibrillator, and mildly symptomatic chronic heart failure. Circulation 2004 110 : 2864 2868.
12. Saxon LA, Greenfield RA, Crandall BG, Nydegger CC, Orlov M, VAN GR. Results of the multicenter RENEWAL 3 AVT clinical study of cardiac resynchronization defibrillator therapy in patients with paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2006 17 : 520 525.
13. Hugl B, Bruns HJ, Unterberg-Buchwald C, Grosse A, Stegemann B, Lauer B, Geller JC, et al. Atrial fibrillation burden during the post-implant period after CRT using device-based diagnostics. J Cardiovasc Electrophysiol 2006 17 : 813 817.
14. Gasparini M, Auricchio A, Regoli F, Fantoni C, Kawabata M, Galimberti P, Pini D, et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: The importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol 2006 48 : 734 743.
15. Schmitt C, Ndrepepa G, Schmitt C, Ndrepepa G. Use of atrial defibrillators to convert atrial fibrillation at home: Psychosocial aspects[comment]. J Cardiovasc Electrophysiol 2003 14 : 817 818.
16. Rashba EJ, Shorofsky SR, Brown T, Peters RW, Gold MR, Rashba EJ, Shorofsky SR, et al. Clinical predictors of atrial defibrillation thresholds with a dual-coil, active pectoral lead system. Heart Rhythm 2005 2 : 49 54.
17. Serber ER, Sears SF, Sotile RO, Burns JL, Schwartzman DS, Hoyt RH, Alvarez LG, et al. Sleep quality among patients treated with implantable atrial defibrillation therapy: Effect of nocturnal shock delivery and psychological distress. J Cardiovasc Electrophysiol 2003 14 : 960 964.
18. Boriani G, Diemberger I, Biffi M, Martignani C, Ziacchi M, Bertini M, Valzania C, et al. How, why, and when may atrial defibrillation find a specific role in implantable devices? A clinical viewpoint [Review;91 refs]. Pacing Clin Electrophysiol 2007 30 : 422 433.
19. Josephson ME, Josephson ME. New approaches to the management of atrial fibrillation. The role of the atrial defibrillator. Circulation 1998 98 : 1594 1596.
20. Scheinman MM, Morady F, Scheinman MM, Morady F. Nonpharmacological approaches to atrial fibrillation [see comment] [Review;45 refs]. Circulation 2001 103 : 2120 2125.
21. Timmermans C, Levy S, Ayers GM, Jung W, Jordaens L, Rosenqvist M, Thibault B, et al. Spontaneous episodes of atrial fibrillation after implantation of the Metrix atrioverter: Observations on treated and nontreated episodes. Metrix Investigators. J Am Coll Cardiol 2000 35 : 1428 1433.
22. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 2001 7 : 176 182.
23. Friedman PA, Dijkman B, Warman EN, Xia HA, Mehra R, Stanton MS, Hammill SC. Atrial therapies reduce atrial arrhythmia burden in defibrillator patients. Circulation 2001 104 : 1023 1028.
24. Capucci A, Boriani G, Botto GL, Lenzi T, Rubino I, Falcone C, Trisolino G, et al. Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol 1994 74 : 503 505.
25. Boriani G, Biffi M, Capucci A, Botto GL, Broffoni T, Rubino I, Della CS, et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial [see comment]. Ann Intern Med 1997 126 : 621 625.
26. Hohnloser SH, van de LA, Baedeker F, Hohnloser SH, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995 26 : 852 858.
27. Volgman AS, Carberry PA, Stambler B, Lewis WR, Dunn GH, Perry KT, Vanderlugt JT, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998 31 : 1414 1419.
28. Capucci A, Lenzi T, Boriani G, Trisolino G, Binetti N, Cavazza M, Fontana G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992 70 : 69 72.
29. Chou CK, Chen GW, Guy AW, Luk KH. Formulas for preparing phantom muscle tissue at various radiofrequencies. Bioelectromagnetics 1984 5 : 435 441.
30. SA. 1346: Sharing between the meteorological aids service and medical implant communication systems (MICS) operating in the mobile service in the frequency band 401-406 MHz. International Telecommunications Union, 2007.
31. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001 285 : 2370 2375.
32. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG, Feinberg WM, Blackshear JL, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995 155 : 469 473.
33. European Heart Rhythm Association and the Heart Rhythm Society Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol 2006 48 : e149 e246.
34. Flegel KM, Shipley MJ, Rose G, Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation [erratum appears in Lancet 1987; 1:878]. Lancet 1987 1 : 526 529.
35. Murgatroyd FD, Gibson SM, Baiyan X, O'Nunain S, Poloniecki JD, Ward DE, Malik M, et al. Double-blind placebo-controlled trial of digoxin in symptomatic paroxsymal atrial fibrillation. Circulation 1999 99 : 2765 2770.
36. Fung JW, Yu CM, Chan JY, Chan HC, Yip GW, Zhang Q, Sanderson JE. Effects of cardiac resynchronization therapy on incidence of atrial fibrillation in patients with poor left ventricular systolic function. Am J Cardiol 2005 96 : 728 731.
37. Lau CP, Tse HF, Lok NS, Lee KL, Ho DS, Sopher M, Murgatroyd F, et al. Initial clinical experience with an implantable human atrial defibrillator. Pacing Clin Electrophysiol 1997 20 (1 Pt 2 220 225.
38. Mitchell AR, Mitchell ARJ. 'The patient takes charge'-long term use of the atrial defibrillator [comment]. Eur Heart J 2003 24 : 2075 2076.
39. Burns JL, Sears SF, Sotile R, Schwartzman DS, Hoyt RH, Alvarez LG, Ujhelyi MR. Do patients accept implantable atrial defibrillation therapy? Results from the Patient Atrial Shock Survey of Acceptance and Tolerance (PASSAT) Study [see comment]. J Cardiovasc Electrophysiol 2004 15 : 286 291.
40. Fabian TJ, Schwartzman DS, Ujhelyi MR, Corey SE, Bigos KL, Pollock BG, Kroboth PD, et al. Decreasing pain and anxiety associated with patient-activated atrial shock: A placebo-controlled study of adjunctive sedation with oral triazolam [see comment]. J Cardiovasc Electrophysiol 2006 17 : 391 395.
41. Boodhoo L, Mitchell A, Ujhelyi M, Sulke N, Boodhoo L, Mitchell A, Ujhelyi M, et al. Improving the acceptability of the atrial defibrillator: Patient-activated cardioversion versus automatic night cardioversion with and without sedation (ADSAS 2). Pacing Clin Electrophysiol 2004 27 : 910 917.
42. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, et al., Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure [see comment][erratum appears in N Engl J Med 2005; 352:2146]. N Engl J Med 2005 352 : 225 237.